{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T21:51:23Z","timestamp":1791582683948,"version":"4.3.4"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Naunyn-Schmiedeberg's Arch Pharmacol"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s00210-026-05635-9","type":"journal-article","created":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T11:27:28Z","timestamp":1782905248000},"page":"19949-19971","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Glucagon-like peptide-1 receptor agonists in neurodegenerative diseases: a bibliometric analysis of global research trends and research hotspots from 2006 to 2025"],"prefix":"10.1007","volume":"399","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-2343-0068","authenticated-orcid":false,"given":"Qinsheng","family":"Bi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-3342-8612","authenticated-orcid":false,"given":"Liangyi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-1897-7120","authenticated-orcid":false,"given":"Jiaxin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-5223-7460","authenticated-orcid":false,"given":"Xin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-9300-8113","authenticated-orcid":false,"given":"Changlin","family":"Zuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-8265-0535","authenticated-orcid":false,"given":"Shijie","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-5330-6703","authenticated-orcid":false,"given":"Zairong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-6167-4842","authenticated-orcid":false,"given":"Zilin","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-3900-1967","authenticated-orcid":false,"given":"Hejia","family":"Wan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,1]]},"reference":[{"issue":"4","key":"5635_CR1","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1016\/j.joi.2017.08.007","volume":"11","author":"M Aria","year":"2017","unstructured":"Aria M, Cuccurullo C (2017) Bibliometrix: an R-tool for comprehensive science mapping analysis. J Informetr 11(4):959\u2013975. https:\/\/doi.org\/10.1016\/j.joi.2017.08.007","journal-title":"J Informetr"},{"issue":"1","key":"5635_CR2","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1080\/1364557032000119616","volume":"8","author":"H Arksey","year":"2005","unstructured":"Arksey H, O\u2019Malley L (2005) Scoping studies: towards a methodological framework. Int J Soc Res Methodol 8(1):19\u201332. https:\/\/doi.org\/10.1080\/1364557032000119616","journal-title":"Int J Soc Res Methodol"},{"issue":"1","key":"5635_CR3","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/75556","volume":"25","author":"M Ashburner","year":"2000","unstructured":"Ashburner M, Ball CA, Blake JA et al (2000) Gene Ontology: tool for the unification of biology. Nat Genet 25(1):25\u201329. https:\/\/doi.org\/10.1038\/75556","journal-title":"Nat Genet"},{"issue":"5","key":"5635_CR4","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1016\/j.drudis.2016.01.013","volume":"21","author":"D Athauda","year":"2016","unstructured":"Athauda D, Foltynie T (2016) The glucagon-like peptide 1 receptor as a therapeutic target in Parkinson\u2019s disease: mechanisms of action. Drug Discov Today 21(5):802\u2013818. https:\/\/doi.org\/10.1016\/j.drudis.2016.01.013","journal-title":"Drug Discov Today"},{"issue":"10103","key":"5635_CR5","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.1016\/S0140-6736(17)31585-4","volume":"390","author":"D Athauda","year":"2017","unstructured":"Athauda D, Maclagan K, Skene SS, Bajwa-Joseph M, Letchford D, Chowdhury K et al (2017) Exenatide once weekly versus placebo in Parkinson\u2019s disease: a randomised, double-blind, placebo-controlled trial. Lancet 390(10103):1664\u20131675. https:\/\/doi.org\/10.1016\/S0140-6736(17)31585-4","journal-title":"Lancet"},{"issue":"10103","key":"5635_CR6","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.1016\/S0140-6736(17)31585-4","volume":"390","author":"D Athauda","year":"2017","unstructured":"Athauda D, Maclagan K, Skene SS et al (2017) Exenatide once weekly versus placebo in Parkinson\u2019s disease: a randomised, double-blind, placebo-controlled trial. Lancet 390(10103):1664\u20131675. https:\/\/doi.org\/10.1016\/S0140-6736(17)31585-4","journal-title":"Lancet"},{"issue":"2","key":"5635_CR7","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1002\/jnr.21483","volume":"86","author":"G Bertilsson","year":"2008","unstructured":"Bertilsson G, Patrone C, Zachrisson O et al (2008) Peptide hormone exendin-4 stimulates subventricular zone neurogenesis in the adult rodent brain and induces recovery in an animal model of Parkinson\u2019s disease. J Neurosci Res 86(2):326\u2013338. https:\/\/doi.org\/10.1002\/jnr.21483","journal-title":"J Neurosci Res"},{"issue":"10","key":"5635_CR8","doi-asserted-by":"publisher","first-page":"3067","DOI":"10.1093\/brain\/awaa262","volume":"143","author":"R Brauer","year":"2020","unstructured":"Brauer R, Wei L, Ma T, Athauda D, Girges C, Vijiaratnam N et al (2020) Diabetes medications and risk of Parkinson\u2019s disease: a cohort study of patients with diabetes. Brain 143(10):3067\u20133076. https:\/\/doi.org\/10.1093\/brain\/awaa262","journal-title":"Brain"},{"issue":"3","key":"5635_CR9","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1002\/asi.20317","volume":"57","author":"C Chen","year":"2006","unstructured":"Chen C (2006) CiteSpace II: detecting and visualizing emerging trends and transient patterns in scientific literature. J Am Soc Inf Sci Technol 57(3):359\u2013377. https:\/\/doi.org\/10.1002\/asi.20317","journal-title":"J Am Soc Inf Sci Technol"},{"key":"5635_CR10","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s13195-024-01666-7","volume":"17","author":"JL Cummings","year":"2025","unstructured":"Cummings JL, Atri A, Feldman HH et al (2025) evoke and evoke+: design of two large-scale, double-blind, placebo-controlled, phase 3 studies evaluating efficacy, safety, and tolerability of semaglutide in early-stage symptomatic Alzheimer\u2019s disease. Alzheimers Res Ther 17:14. https:\/\/doi.org\/10.1186\/s13195-024-01666-7","journal-title":"Alzheimers Res Ther"},{"key":"5635_CR11","first-page":"100133","volume":"6","author":"S Dahiya","year":"2022","unstructured":"Dahiya S, Salari M, Ramtin S et al (2022) The effect of GLP-1 receptor agonists in pre-clinical rodent models of Parkinson\u2019s disease: a systematic review and meta-analysis. Clin Park Relat Disord 6:100133","journal-title":"Clin Park Relat Disord"},{"key":"5635_CR12","doi-asserted-by":"publisher","unstructured":"De Giorgi R, Ghenciulescu A, Yotter C, Taquet M, Koychev I (2025) Glucagon-like peptide-1 receptor agonists for major neurocognitive disorders. J Neurol Neurosurg Psychiatry. 96(9):870\u2013883. Published 2025 Aug 14. https:\/\/doi.org\/10.1136\/jnnp-2024-335593","DOI":"10.1136\/jnnp-2024-335593"},{"issue":"6","key":"5635_CR13","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1177\/193229680800200619","volume":"2","author":"SM de la Monte","year":"2008","unstructured":"de la Monte SM, Wands JR (2008) Alzheimer\u2019s disease is type 3 diabetes\u2014evidence reviewed. J Diabetes Sci Technol 2(6):1101\u20131113. https:\/\/doi.org\/10.1177\/193229680800200619","journal-title":"J Diabetes Sci Technol"},{"issue":"17","key":"5635_CR14","doi-asserted-by":"publisher","first-page":"9583","DOI":"10.3390\/ijms23179583","volume":"23","author":"Y Diz-Chaves","year":"2022","unstructured":"Diz-Chaves Y, Mastoor Z, Spuch C, Gonz\u00e1lez-Mat\u00edas LC, Mallo F (2022) Anti-inflammatory effects of GLP-1 receptor activation in the brain in neurodegenerative diseases. Int J Mol Sci 23(17):9583. https:\/\/doi.org\/10.3390\/ijms23179583","journal-title":"Int J Mol Sci"},{"key":"5635_CR15","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.jbusres.2021.04.070","volume":"133","author":"N Donthu","year":"2021","unstructured":"Donthu N, Kumar S, Mukherjee D, Pandey N, Lim WM (2021) How to conduct a bibliometric analysis: an overview and guidelines. J Bus Res 133:285\u2013296. https:\/\/doi.org\/10.1016\/j.jbusres.2021.04.070","journal-title":"J Bus Res"},{"issue":"3","key":"5635_CR16","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.cmet.2006.01.004","volume":"3","author":"DJ Drucker","year":"2006","unstructured":"Drucker DJ (2006) The biology of incretin hormones. Cell Metab 3(3):153\u2013165. https:\/\/doi.org\/10.1016\/j.cmet.2006.01.004","journal-title":"Cell Metab"},{"key":"5635_CR17","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a028035","author":"BN Dugger","year":"2017","unstructured":"Dugger BN, Dickson DW (2017) Pathology of neurodegenerative diseases. Cold Spring Harb Perspect Biol. https:\/\/doi.org\/10.1101\/cshperspect.a028035","journal-title":"Cold Spring Harb Perspect Biol"},{"issue":"1","key":"5635_CR18","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1038\/s41591-025-04106-7","volume":"32","author":"P Edison","year":"2026","unstructured":"Edison P, Femminella GD, Ritchie CW et al (2026) Liraglutide in mild to moderate Alzheimer\u2019s disease: a phase 2b clinical trial. Nat Med 32(1):353\u2013361. https:\/\/doi.org\/10.1038\/s41591-025-04106-7","journal-title":"Nat Med"},{"issue":"2","key":"5635_CR19","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1096\/fj.07-9492LSF","volume":"22","author":"ME Falagas","year":"2008","unstructured":"Falagas ME, Pitsouni EI, Malietzis GA, Pappas G (2008) Comparison of PubMed, Scopus, Web of Science, and Google Scholar: strengths and weaknesses. FASEB J 22(2):338\u2013342. https:\/\/doi.org\/10.1096\/fj.07-9492LSF","journal-title":"FASEB J"},{"key":"5635_CR20","doi-asserted-by":"publisher","unstructured":"GBD 2019 Dementia Forecasting Collaborators. Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050. Lancet Public Health. 2022;7(2)\u2013e125. https:\/\/doi.org\/10.1016\/S2468-2667(21)00249-8.","DOI":"10.1016\/S2468-2667(21)00249-8"},{"issue":"4","key":"5635_CR21","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1016\/S1474-4422(15)70016-5","volume":"14","author":"MT Heneka","year":"2015","unstructured":"Heneka MT, Carson MJ, El Khoury J et al (2015) Neuroinflammation in Alzheimer\u2019s disease. Lancet Neurol 14(4):388\u2013405. https:\/\/doi.org\/10.1016\/S1474-4422(15)70016-5","journal-title":"Lancet Neurol"},{"issue":"1","key":"5635_CR22","doi-asserted-by":"publisher","first-page":"T41","DOI":"10.1530\/JOE-13-0221","volume":"221","author":"C H\u00f6lscher","year":"2014","unstructured":"H\u00f6lscher C (2014) Central effects of GLP-1: new opportunities for treatments of neurodegenerative diseases. J Endocrinol. 221(1):T41. https:\/\/doi.org\/10.1530\/JOE-13-0221","journal-title":"J Endocrinol."},{"issue":"1","key":"5635_CR23","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1186\/s12929-024-01090-x","volume":"31","author":"CT Hong","year":"2024","unstructured":"Hong CT, Chen JH, Hu CJ (2024) Role of glucagon-like peptide-1 receptor agonists in Alzheimer\u2019s disease and Parkinson\u2019s disease. J Biomed Sci 31(1):102. https:\/\/doi.org\/10.1186\/s12929-024-01090-x","journal-title":"J Biomed Sci"},{"issue":"1","key":"5635_CR24","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1093\/nar\/28.1.27","volume":"28","author":"M Kanehisa","year":"2000","unstructured":"Kanehisa M, Goto S (2000) KEGG: Kyoto Encyclopedia of Genes and Genomes. Nucleic Acids Res 28(1):27\u201330. https:\/\/doi.org\/10.1093\/nar\/28.1.27","journal-title":"Nucleic Acids Res"},{"issue":"9","key":"5635_CR25","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1016\/S1474-4422(20)30231-3","volume":"19","author":"D Kellar","year":"2020","unstructured":"Kellar D, Craft S (2020) Brain insulin resistance in Alzheimer\u2019s disease and related disorders. Lancet Neurol 19(9):758\u2013766. https:\/\/doi.org\/10.1016\/S1474-4422(20)30231-3","journal-title":"Lancet Neurol"},{"key":"5635_CR26","doi-asserted-by":"publisher","first-page":"1205207","DOI":"10.3389\/fphar.2023.1205207","volume":"14","author":"F Kong","year":"2023","unstructured":"Kong F, Wu T, Dai J, Zhai Z, Cai J, Zhu Z, Xu Y, Sun T (2023) Glucagon-like peptide 1 (GLP-1) receptor agonists in experimental Alzheimer\u2019s disease models: a systematic review and meta-analysis of preclinical studies. Front Pharmacol 14:1205207. https:\/\/doi.org\/10.3389\/fphar.2023.1205207","journal-title":"Front Pharmacol"},{"key":"5635_CR27","doi-asserted-by":"publisher","first-page":"106550","DOI":"10.1016\/j.phrs.2022.106550","volume":"186","author":"KO Kopp","year":"2022","unstructured":"Kopp KO, Glotfelty EJ, Li Y, Greig NH (2022) Glucagon-like peptide-1 receptor agonists and neuroinflammation: implications for neurodegenerative disease treatment. Pharmacol Res 186:106550. https:\/\/doi.org\/10.1016\/j.phrs.2022.106550","journal-title":"Pharmacol Res"},{"issue":"4","key":"5635_CR28","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1007\/s00520-026-10589-y","volume":"34","author":"F Li","year":"2026","unstructured":"Li F, Wan H, Liu X, Deng Y, Tian W, Zhao Z (2026) Application of auriculotherapy in cancer-related fatigue symptom cluster: a scoping review. Support Care Cancer 34(4):351. https:\/\/doi.org\/10.1007\/s00520-026-10589-y","journal-title":"Support Care Cancer"},{"issue":"1","key":"5635_CR29","doi-asserted-by":"publisher","first-page":"777","DOI":"10.3233\/ADR-230181","volume":"8","author":"Y Liang","year":"2024","unstructured":"Liang Y, Dor\u00e9 V, Rowe CC, Krishnadas N (2024) Clinical evidence for GLP-1 receptor agonists in Alzheimer\u2019s disease: a systematic review. J Alzheimers Dis Rep 8(1):777\u2013789. https:\/\/doi.org\/10.3233\/ADR-230181","journal-title":"J Alzheimers Dis Rep"},{"issue":"10452","key":"5635_CR30","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1016\/S0140-6736(24)01296-0","volume":"404","author":"G Livingston","year":"2024","unstructured":"Livingston G, Huntley J, Liu KY et al (2024) Dementia prevention, intervention, and care: 2024 report of the Lancet standing commission. Lancet 404(10452):572\u2013628. https:\/\/doi.org\/10.1016\/S0140-6736(24)01296-0","journal-title":"Lancet"},{"issue":"17","key":"5635_CR31","doi-asserted-by":"publisher","first-page":"6587","DOI":"10.1523\/JNEUROSCI.0529-11.2011","volume":"31","author":"PL McClean","year":"2011","unstructured":"McClean PL, Parthsarathy V, Faivre E, H\u00f6lscher C (2011) The diabetes drug liraglutide prevents degenerative processes in a mouse model of Alzheimer\u2019s disease. J Neurosci 31(17):6587\u20136594. https:\/\/doi.org\/10.1523\/JNEUROSCI.0529-11.2011","journal-title":"J Neurosci"},{"issue":"1","key":"5635_CR32","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/S1474-4422(23)00378-2","volume":"23","author":"A McGarry","year":"2024","unstructured":"McGarry A, Rosanbalm S, Leinonen M, Olanow CW, To D, Bell A et al (2024) Safety, tolerability, and efficacy of NLY01 in early untreated Parkinson\u2019s disease: a randomised, double-blind, placebo-controlled trial. Lancet Neurol 23(1):37\u201345. https:\/\/doi.org\/10.1016\/S1474-4422(23)00378-2","journal-title":"Lancet Neurol"},{"issue":"13","key":"5635_CR33","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1056\/NEJMoa2312323","volume":"390","author":"WG Meissner","year":"2024","unstructured":"Meissner WG, Remy P, Giordana C, Malt\u00eate D, Derkinderen P, Houeto JL et al (2024) Trial of lixisenatide in early Parkinson\u2019s disease. N Engl J Med 390(13):1176\u20131185. https:\/\/doi.org\/10.1056\/NEJMoa2312323","journal-title":"N Engl J Med"},{"issue":"2","key":"5635_CR34","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1161\/STROKEAHA.125.053075","volume":"57","author":"MK Michaelsen","year":"2026","unstructured":"Michaelsen MK, Drasbek KR, Valentin JB et al (2026) GLP-1 receptor agonists as treatment of nondiabetic ischemic stroke: a systematic review and meta-analysis. Stroke 57(2):415\u2013437. https:\/\/doi.org\/10.1161\/STROKEAHA.125.053075","journal-title":"Stroke"},{"key":"5635_CR35","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.molmet.2019.09.010","volume":"30","author":"TD M\u00fcller","year":"2019","unstructured":"M\u00fcller TD, Finan B, Bloom SR et al (2019) Glucagon-like peptide 1 (GLP-1). Mol Metab 30:72\u2013130. https:\/\/doi.org\/10.1016\/j.molmet.2019.09.010","journal-title":"Mol Metab"},{"key":"5635_CR36","doi-asserted-by":"publisher","unstructured":"Mulvaney CA, Duarte GS, Handley J, Evans DJ, Menon S, Wyse R, Emsley HC (2020) GLP-1 receptor agonists for Parkinson\u2019s disease. Cochrane Database Syst Rev. 7(7). https:\/\/doi.org\/10.1002\/14651858.CD012990.pub2","DOI":"10.1002\/14651858.CD012990.pub2"},{"key":"5635_CR37","doi-asserted-by":"publisher","first-page":"101102","DOI":"10.1016\/j.molmet.2020.101102","volume":"46","author":"MA Nauck","year":"2021","unstructured":"Nauck MA, Quast DR, Wefers J, Meier JJ (2021) GLP-1 receptor agonists in the treatment of type 2 diabetes\u2014state-of-the-art. Mol Metab 46:101102. https:\/\/doi.org\/10.1016\/j.molmet.2020.101102","journal-title":"Mol Metab"},{"issue":"6301","key":"5635_CR38","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1126\/science.aag2590","volume":"353","author":"RM Ransohoff","year":"2016","unstructured":"Ransohoff RM (2016) How neuroinflammation contributes to neurodegeneration. Science 353(6301):777\u2013783. https:\/\/doi.org\/10.1126\/science.aag2590","journal-title":"Science"},{"key":"5635_CR39","doi-asserted-by":"publisher","first-page":"970925","DOI":"10.3389\/fnins.2022.970925","volume":"16","author":"N Reich","year":"2022","unstructured":"Reich N, H\u00f6lscher C (2022) The neuroprotective effects of glucagon-like peptide 1 in Alzheimer\u2019s and Parkinson\u2019s disease: an in-depth review. Front Neurosci 16:970925. https:\/\/doi.org\/10.3389\/fnins.2022.970925","journal-title":"Front Neurosci"},{"issue":"4","key":"5635_CR40","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1016\/S1474-4422(24)00038-3","volume":"23","author":"JD Steinmetz","year":"1990","unstructured":"Steinmetz JD, Seeher KM, Schiess N et al (1990) Global, regional, and national burden of disorders affecting the nervous system, 1990\u20132021: a systematic analysis for the Global Burden of Disease Study 2021. Lancet Neurol 23(4):344\u2013381. https:\/\/doi.org\/10.1016\/S1474-4422(24)00038-3","journal-title":"Lancet Neurol"},{"key":"5635_CR41","doi-asserted-by":"publisher","first-page":"1525623","DOI":"10.3389\/fimmu.2025.1525623","volume":"16","author":"H Sun","year":"2025","unstructured":"Sun H, Zhang Y, Liu J et al (2025) The immunomodulatory effects of GLP-1 receptor agonists in neurological diseases. Front Immunol 16:1525623. https:\/\/doi.org\/10.3389\/fimmu.2025.1525623","journal-title":"Front Immunol"},{"issue":"D1","key":"5635_CR42","doi-asserted-by":"publisher","first-page":"D638","DOI":"10.1093\/nar\/gkac1000","volume":"51","author":"D Szklarczyk","year":"2023","unstructured":"Szklarczyk D, Kirsch R, Koutrouli M et al (2023) The STRING database in 2023: protein-protein association networks and functional enrichment analyses for any sequenced genome of interest. Nucleic Acids Res 51(D1):D638\u2013D646. https:\/\/doi.org\/10.1093\/nar\/gkac1000","journal-title":"Nucleic Acids Res"},{"issue":"11","key":"5635_CR43","doi-asserted-by":"publisher","first-page":"1960","DOI":"10.1002\/mds.29992","volume":"39","author":"H Tang","year":"2024","unstructured":"Tang H, Lu Y, Okun MS, Donahoo WT, Ramirez-Zamora A, Wang F et al (2024) Glucagon-like peptide-1 receptor agonists and risk of Parkinson\u2019s disease in patients with type 2 diabetes: a population-based cohort study. Mov Disord 39(11):1960\u20131970. https:\/\/doi.org\/10.1002\/mds.29992","journal-title":"Mov Disord"},{"issue":"7","key":"5635_CR44","doi-asserted-by":"publisher","first-page":"467","DOI":"10.7326\/M18-0850","volume":"169","author":"AC Tricco","year":"2018","unstructured":"Tricco AC, Lillie E, Zarin W, O\u2019Brien KK, Colquhoun H, Levac D et al (2018) PRISMA extension for scoping reviews: checklist and explanation. Ann Intern Med 169(7):467\u2013473. https:\/\/doi.org\/10.7326\/M18-0850","journal-title":"Ann Intern Med"},{"issue":"2","key":"5635_CR45","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1007\/s11192-009-0146-3","volume":"84","author":"NJ van Eck","year":"2010","unstructured":"van Eck NJ, Waltman L (2010) Software survey: VOSviewer, a computer program for bibliometric mapping. Scientometrics 84(2):523\u2013538. https:\/\/doi.org\/10.1007\/s11192-009-0146-3","journal-title":"Scientometrics"},{"issue":"10479","key":"5635_CR46","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1016\/S0140-6736(24)02808-3","volume":"405","author":"N Vijiaratnam","year":"2025","unstructured":"Vijiaratnam N, Girges C, Auld G, McComish R et al (2025) Exenatide once a week versus placebo as a potential disease-modifying treatment for people with Parkinson\u2019s disease in the UK: a phase 3, multicentre, double-blind, parallel-group, randomised, placebo-controlled trial. Lancet 405(10479):627\u2013636. https:\/\/doi.org\/10.1016\/S0140-6736(24)02808-3","journal-title":"Lancet"},{"key":"5635_CR47","doi-asserted-by":"publisher","first-page":"4877","DOI":"10.2147\/JMDH.S482100","volume":"17","author":"H Wan","year":"2024","unstructured":"Wan H, Wei B, Qian W, Zhang J (2024a) Trends and hotspots in the health economics evaluation of chronic fatigue syndrome. J Multidiscip Healthc 17:4877\u20134892. https:\/\/doi.org\/10.2147\/JMDH.S482100","journal-title":"J Multidiscip Healthc"},{"key":"5635_CR48","doi-asserted-by":"publisher","first-page":"1499025","DOI":"10.3389\/fnins.2024.1499025","volume":"18","author":"H Wan","year":"2024","unstructured":"Wan H, Qian W, Wei B, Tian K, Chen Z, Zhang J, Chen F (2024b) A bibliometric analysis of gene editing and amyotrophic lateral sclerosis from 2004 to 2024. Front Neurosci 18:1499025. https:\/\/doi.org\/10.3389\/fnins.2024.1499025","journal-title":"Front Neurosci"},{"issue":"12","key":"5635_CR49","doi-asserted-by":"publisher","first-page":"8661","DOI":"10.1002\/alz.14313","volume":"20","author":"W Wang","year":"2024","unstructured":"Wang W, Wang Q, Qi X et al (2024) Associations of semaglutide with first-time diagnosis of Alzheimer\u2019s disease in patients with type 2 diabetes: target trial emulation using nationwide real-world data in the US. Alzheimers Dement 20(12):8661\u20138672. https:\/\/doi.org\/10.1002\/alz.14313","journal-title":"Alzheimers Dement"},{"key":"5635_CR50","doi-asserted-by":"publisher","first-page":"1790658","DOI":"10.3389\/fnmol.2026.1790658","volume":"19","author":"X Wang","year":"2026","unstructured":"Wang X, Wan H, Liu X, Tian W, Liu Y, Zhao Z, Wang X (2026) Application of auricular therapy in postherpetic neuralgia: a scoping review. Front Mol Neurosci 19:1790658. https:\/\/doi.org\/10.3389\/fnmol.2026.1790658","journal-title":"Front Mol Neurosci"},{"key":"5635_CR51","doi-asserted-by":"publisher","first-page":"600468","DOI":"10.2147\/CIA.S600468","volume":"21","author":"B Xu","year":"2026","unstructured":"Xu B, Wan H, Liu P, Zhao Z, Xie Y, Meng J, Qin Y (2026) Application of photostimulation therapy in cognitive function of Alzheimer\u2019s disease patients: a scoping review. Clin Interv Aging 21:600468. https:\/\/doi.org\/10.2147\/CIA.S600468","journal-title":"Clin Interv Aging"},{"key":"5635_CR52","doi-asserted-by":"publisher","first-page":"1742805","DOI":"10.3389\/fnagi.2026.1742805","volume":"18","author":"J Zhang","year":"2026","unstructured":"Zhang J, Zhao Z, Xiang T, Teng D, Wan H, Zhang Q, Liu X (2026) From knowledge landscapes to network mechanisms: charting regulated cell death pathways in ALS. Front Aging Neurosci 18:1742805. https:\/\/doi.org\/10.3389\/fnagi.2026.1742805","journal-title":"Front Aging Neurosci"},{"key":"5635_CR53","doi-asserted-by":"publisher","DOI":"10.1016\/j.wneu.2026.125091","author":"Z Zhao","year":"2006","unstructured":"Zhao Z, Wan H, Wang X et al (2006) Blueprints of care: a two-decade global bibliometric atlas of neurosurgical nursing (2006-2025). World Neurosurg. https:\/\/doi.org\/10.1016\/j.wneu.2026.125091","journal-title":"World Neurosurg"}],"container-title":["Naunyn-Schmiedeberg's Archives of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-026-05635-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00210-026-05635-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-026-05635-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T21:03:01Z","timestamp":1791579781000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00210-026-05635-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,1]]},"references-count":53,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["5635"],"URL":"https:\/\/doi.org\/10.1007\/s00210-026-05635-9","relation":{},"ISSN":["0028-1298","1432-1912"],"issn-type":[{"value":"0028-1298","type":"print"},{"value":"1432-1912","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,1]]},"assertion":[{"value":"10 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Acknowledging the use of artificial intelligence-assisted tools for language polishing and grammatical refinement, the authors confirm that such tools were applied exclusively for improving linguistic clarity. All substantive academic content, analyses, and interpretations remain the sole responsibility of the authors.","order":1,"name":"Ethics","label":"Generative AI statement","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No specific clinical resources websites applicable to this article are included.","order":2,"name":"Ethics","label":"Clinical resources","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethical approval was not required for this work as it did not involve human or animal subjects. No data collection from human participants or animals occurred.","order":3,"name":"Ethics","label":"Ethics declaration","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors listed above have reviewed the final version of this manuscript and consent to its submission for publication. We affirm that this work is original, has not been published previously, and is not under consideration elsewhere. If accepted, all authors approve its publication in its present form and will grant the Journal an exclusive license to publish the article.","order":4,"name":"Ethics","label":"Consent to publish","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This Declaration does not apply.","order":5,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":6,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}]}}